HUNT DOUGLAS M 4

What Happened
Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology (PBYI), received two equity awards on February 18, 2026: 49,394 restricted stock units (RSUs) and a derivative award covering 70,321 shares (reported as a grant at $0.00). Each award was reported with a $0.00 acquisition price, which is typical for compensation grants and does not represent an open-market purchase or sale.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026. No late-filing flag indicated in the report.
• Awards reported: 49,394 RSUs (F1) and 70,321 derivative awards/options (A; F2).
• Reported acquisition price: $0.00 for both grants (i.e., awards, not paid purchases).
• Vesting (per footnotes): Each award vests 1/4 on each of July 1, 2026; Jan 1, 2027; July 1, 2027; and Jan 1, 2028, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing summary.
• Role: Reporting person is the Company’s Senior Vice President of Regulatory Affairs.

Context
These entries are grants of compensation (RSUs and options) rather than purchases or sales. RSUs convert to shares upon vesting; the derivative/option award vests per the same schedule and becomes exercisable as it vests (footnote F2). Such grants are routine executive compensation intended for retention/incentive and do not, by themselves, signal a buy or sell decision in the market.